Pharmaxis raises new funds for lead therapeutic
This article was originally published in Scrip
Executive Summary
Pharmaxis has raised A$47 million ($37.6 million) in new funding which it will use mainly to support the commercialisation of its lead therapeutic product in the US and Europe.